Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Cancer CommunicationsVolume 40, Issue 4 p. 197-201 LETTER TO THE EDITOROpen Access Clinicopathological features of pseudomyogenic hemangioendothelioma and precision therapy based on whole exome sequencing Junqiang Wei, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, 067000 P. R. China Junqiang Wei and Zhichao Liao contributed equally to this work.Search for more papers by this authorZhichao Liao, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Junqiang Wei and Zhichao Liao contributed equally to this work.Search for more papers by this authorGang Zhao, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorNazmun Nahar, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China International Medical School, Tianjin Medical University, Tianjin, 300061 P. R. ChinaSearch for more papers by this authorChao Zhang, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorJia Lu, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorYun Yang, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorJilong Yang, Corresponding Author yangjilong@tjmuch.com Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Correspondence Prof. Jilong Yang, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P. R. China. Email: yangjilong@tjmuch.comSearch for more papers by this author Junqiang Wei, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Department of Orthopedics, Affiliated Hospital of Chengde Medical College, Chengde, Hebei, 067000 P. R. China Junqiang Wei and Zhichao Liao contributed equally to this work.Search for more papers by this authorZhichao Liao, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Junqiang Wei and Zhichao Liao contributed equally to this work.Search for more papers by this authorGang Zhao, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorNazmun Nahar, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China International Medical School, Tianjin Medical University, Tianjin, 300061 P. R. ChinaSearch for more papers by this authorChao Zhang, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorJia Lu, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorYun Yang, Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. ChinaSearch for more papers by this authorJilong Yang, Corresponding Author yangjilong@tjmuch.com Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060 P. R. China Correspondence Prof. Jilong Yang, Huanhu Xi Road, Tiyuan Bei, Hexi District, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P. R. China. Email: yangjilong@tjmuch.comSearch for more papers by this author First published: 30 March 2020 https://doi.org/10.1002/cac2.12020 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat Abbreviations CK cytokeratin EA epithelial angiosarcoma EHE epithelial hemangioendothelial EMA epithelial membrane antigen ERG ETS-related gene ES epithelioid sarcoma FLI-1 freund's leukemia integration site 1 INI-1 integrase interactor-1 PET-CT positron emission tomography-computed tomography PHE pseudomyogenic hemangioendothelioma SKP2 phase kinase-associated protein 2 SMA smooth muscle actin WES whole exome sequence Dear Editor Pseudomyogenic hemangioendothelioma (PHE) is a newly recognized subtype of hemangioendothelioma characterized by the presence of fibrohistiocytic and myoid cells arranged in a fibroma-like or dermatofibroma-like pattern [1]. This rare type of tumor was first named by Hornick and Fletcher [2] and categorized as the novel soft tissue tumor classification system of the World Health Organization in 2013 [3]. Prior to this, it was referred to as fibroma-like variant of epithelioid sarcoma (ES) and epithelioid sarcoma-like hemangioendothelioma [4]. Reported literature describing PHE showed that more than 65% of cases present with multifocal lesions may involve the derma, subcutaneous tissue, muscle, and bone simultaneously [5], and may make some lesions difficult to resect [5]. Furthermore, PHE has been found to be associated with a significant risk of local-regional recurrence of nearly 36% after surgical resection [2]. Clearly, the therapeutic dilemma of PHE is challenged by unresectability and high recurrence risk. However, as a rare subtype of hemangioendothelioma, no effective systemic therapy has been established for unresectable PHE. In the present study, we report two PHE patients who suffered from recurrence and metastasis after an initial operation. Their initial pathological diagnosis was misdiagnosed as ES based on previous histological examination. Case 1 is from a 51-year-old woman who presented with a recurrent soft tissue tumor combined with skin ulceration in her right calf after local resection at the Tianjin Changzheng Hospital (Hongqiao District, Tianjin, China) on December 15, 2017. She was referred to our department, where paraffin-embedded sections from the previous operations were reviewed for immunohistochemistry staining which was positive for cytokeratin (CK), CK19, vimentin, CD31, ETS-related gene (ERG), Freund's leukemia integration site 1 (FLI-1), and integrase interactor 1 (INI-1), but negative for CD34, CD68, CK5/6, CK8/18, epithelial membrane antigen (EMA), smooth muscle actin (SMA), desmin, and S-100. The patient was thereby diagnosed as PHE based on pathological characteristics and immunohistochemical staining. Furthermore, multifocal lesions in the initial operation area, namely, the subcutis of the right lower leg, and the anterior of the right ankle joint, femur, tibia, acetabulum and ischium, were found via positron emission tomography-computed tomography (PET-CT). Subsequently, on January 25, 2018, she underwent a wide surgical resection of the subcutaneous lesions in her right calf and right ankle joint, as well as bone lesions in her right ilium. Tumor tissue samples were stained by hematoxylin and eosin (H&E) and for immunohistochemical markers (Supplementary Figure 1). The neoplastic cells had a rounded epithelioid shape with a prominent eosinophilic cytoplasm and immunohistochemistry findings were in agreement with the aforementioned immunohistochemistry results. Considering that the tumor was recurrent and residual bone lesions were unresectable, whole exome sequencing (WES) of the fresh neoplasm tissue and adjacent normal tissues was performed to identify tumor-related mutations and formulate the next-step for personalized treatment. Case 1 had mutation of the S-phase kinase-associated protein 2 gene (SKP2, Nucleotide variation: c.536+63_536+64insT) detected by WES (Supplementary Table 1). The gene mutation status for Case 1 is summarized in Figure 1. Because SKP2 is associated with the mammalian target of rapamycin (mTOR) signaling pathway in the Kyoto Encyclopedia of Genes and Genomes database (Supplementary Figure 2), the mTOR inhibitor everolimus was recommended for treatment and was approved by the review board at Tianjin Medical University Cancer Hospital. Written informed consent for everolimus as adjuvant therapy was obtained from the patient. Everolimus (Novartis Pharma Schweiz AG, Schaffhauserstrasse, 4332 Stein, Switzerland) treatment was started at 0.8 mg/m2/d on March 1, 2018, and dose adjustments were made to maintain the drug at a therapeutic level of 10–15 ng/mL. No relapse occurred and the bone lesions were all stable at the last radiological follow-up on March 3, 2019 (Figure 2A-2H). Additionally, the abundance of circulating tumor DNA (ctDNA) in the whole peripheral blood was examined and was 0.17 on February 2, 2018, and was 0.13 on May 19, 2018, and April 10, 2019 (Figure 2I). The overall clinical course of this patient is shown in Figure 2I. The cost of treatment and examination were covered by the patient. FIGURE 1Open in figure viewer The gene mutation status for Case 1. (A) Mutant allele frequency distribution. The allele frequency of mutated genes was 5.08% to 44.58%, with a mean of 9.84%, and median of 6.31%. (B) The frequency of copy number variation (CNV): 52 genes had the CNV of loss status, from 0.82 to 1.19 times; 746 genes had the CNV of gain status, from 3.00 to 4.82 times. (C) The CNV distribution in autosome and sex chromosome FIGURE 2Open in figure viewer Clinical representation of the presented 2 cases. The red arrows represent the location of the corresponding lesions. (A-I) The radiological images and treatment course at different time points of Case 1. PET-CT showing the multifocal lesions in the (A) iliac and (B) femur on admission to our hospital on January 22, 2018, and the standard uptake value (SUV) for 18F-fluorodeoxyglucose (18F-FDG) was 8.7 in lesions of the iliac and femur. PET-CT showing the SUV index for the unresectable lesions in the (C) iliac and (D) femur was decreased to 3.2 during the everolimus treatment. (E-H) The residual lesions in the iliac and femur for was stable on CT-scan during the everolimus treatment on (E) April 10, 2018, (F) May 30, 2019, (G) August 2, 2018, and (H) March 3, 2019. (I) The schematic diagram illustrating the clinical course and follow-up time for Case 1. The abundance of ctDNA was 0.17 after the wide surgical resection and decreased to 0.13 during the everolimus therapy. Lesions were indicated with a red arrow. (J-P) The images of Case 2 lesions at different time points. (J) Dermis lesions at the left buttock. (K-P) PET-CT images showing multifocal distribution of Case 2 lesions at (K) the left acetabulum, (L) left ilium, (M) right scapula, and the third and fifth thoracic vertebrae, (N) sacrum, (O) rib and (P) skull Case 2 is from a 28-year-old male who was admitted to the Tianjin Hospital (Hexi District, Tianjin, China) with a pathological left femoral neck fracture and received total hip arthroplasty on April 21, 2017. ES was diagnosed by pathological examination after surgery. However, because of emerging skin lesions (Figure 2J) in his buttock and left calf after 2 weeks, he visited our bone and soft tissue tumor clinic after ES was diagnosed by initial pathological examination. The tumor section of the bone and an excisional biopsy sample of his dermis lesions were re-examined by H&E and immunohistochemistry staining. Tumor cell morphology showed plump spindle neoplastic cells in plexiform configurations with abundant eosinophilic cytoplasm. The cells of interest were immunoreactive for CK, CD31, ERG, FLI-1, B-cell lymphoma 2 (Bcl-2) and INI-1, and negative for EMA, CD34, SMA, S-100, Sry-related HMG box gene 10 (SOX-10), and D2-40. The bone and dermis lesions were all confirmed to be PHE not ES on May 5, 2017. Simultaneously, multifocal subcutaneous and bone lesions were identified by PET-CT (Figure 2K-2P). However, the patient refused sequencing and treatment due to a health insurance problem, and eventually, he stopped attending our clinic. To date, available data on PHE cases include the 2 current cases and 187 cases from literature have been reviewed (Supplementary Table 2). Of the patients, it was revealed that 142 cases were male and 47 were females, with a male: female ratio of approximately 3:1. The average age was 36 years and the median age was 42 (10-82 years) years. PHE often occurs in different tissue planes. There were 120 (63.5%) cases with a multifocal distribution involving the dermis, subcutaneous tissue, deep muscle tissue, or bone involvement. A solitary lesion existed in 69 (36.5%) cases (Supplementary Table 2). Moreover, the tumor always involved different anatomic regions. For instance, based on the anatomical regions of the lesions in PHE patients reported in literature, the anatomical regions of the human body were divided into the limbs (upper and lower limbs), head and neck, and trunk. The extremities (137/189, 72.5%) were the most common region for PHE, especially the lower extremities (106/189, 56.1%), followed by the upper limb (31/189, 16.4%). The neck and head regions were affected in 11 cases (5.8%) and 41 cases (21.7%) were located in the trunk region (Supplementary Table 2). Based on the reported literature, PHE has a high similarity with ES in its histological profile. The neoplastic cells showed a rounded epithelioid shape with a prominent eosinophilic cytoplasm, mitotic activity was low and nuclear pleomorphism was mild to moderate. The tumors were characterized by sheets and ill-defined nodules, which is why Billings et al. termed them as ES-like hemangioendotheliomas [4, 6]. The rate of misdiagnosis was approximately 39.2% (74/189) for initial pathological diagnosis between 1992 and 2019 (Supplementary Table 2). Moreover, not only ES but also epithelial hemangioendothelioma (EHE) and epithelial angiosarcoma (EA) should be considered as its differential diagnosis (Supplementary Table 3) [4]. Endothelial markers such as CD31, FLI-1 and CD34 were found to be positive in ES, EA and EHE by immunohistochemical staining. However, CD34 was observed to be consistently negative in PHE, while the other endothelial markers were positive. Furthermore, positive INI-1 staining and negative S-100, EMA and SMA immunohistochemical staining are meaningful in the differential diagnosis. In addition, frequent SERPINE1-FOSB or ACTB-FOSB fusion genes can be detected in PHE, not in ES, EA or EHE (Supplementary Table 3). Compared with ES and EA, PHE has a low potential distant metastasis in biological behavior (Supplementary Table 3). Above all, the specific clinical characteristics, immunohistochemical staining and recurrent fusion genes can be used to establish a correct diagnosis. In our presented cases, the two patients were both initially misdiagnosed as ES. They were both referred to our department after which paraffin-embedded sections from previous operations were reviewed for immunohistochemistry staining, and were found to be positive for CK, vimentin, CD31, ERG, FLI-1 and INI-1 but negative for CD34, EMA, SMA, desmin, and S-100 (Supplementary Figure 1B-D). Although the FOSB fusion status was not tested in our cases, the diagnosis of PHE was established based on clinical features, HE staining and immunohistochemistry staining. PHE has an indolent biological behavior with a high rate of local recurrence and low-risk for metastasis after resection [5]. In 110 patients with available follow-up data, the tumors of 62 patients (56.4%) relapsed or metastasized to adjacent organs after initial surgical resection, and even radical surgical resection such as amputation could not prevent the local recurrence and metastasis (Supplementary Table 2). Based on the published literature, adjuvant chemotherapy or radiotherapy did not satisfactorily control the disease. In 13 patients with available adjuvant treatment data, 5 (38.5%) patients had disease that progressed after chemotherapy or radiotherapy (Supplementary Table 2). In contrast, 3 chemoresistant PHE cases achieved promising results after target therapy [7-10]. Therefore, this suggests that targeted therapy seems to more beneficial than traditional treatment in PHE. The two cases that we reported both progressed after initial treatment. It has been confirmed that SKP2 is an important oncogene in many types of cancer, a negative regulator of the mTOR complex and can thereby be targeted by mTOR inhibitors [11-13]. Reported literature demonstrated that the mTOR inhibitor has achieved satisfactory results in treating chemo-resistance PHE cases [7-10]. As mentioned above, case 1 received everolimus treatment which produced a notable local maintenance effect. This is the first study reporting SKP2 mutations in PHE patients. Combined with our cases and reported literature, precision therapy for gene mutations seems to be a strategy for the treatment of this rare type of hemangioendothelioma, especially for the residual or unresectable lesions. The treatment experience in Case 1 also presents a good example of the application of precision therapy in rare diseases. Although patients could achieve a stable status with mTOR inhibitors, a longer follow-up period is still needed because of the indolent biological behavior of PHE. Therefore, we still cannot confirm whether mTOR inhibitors have a curative effect on recurrent or unresectable PHE but they can be used as maintenance therapy with no major side effects. PHE is a rare tumor characterized by multifocal distribution involving different tissue planes. It can be easily misdiagnosed, so specific immunochemical staining is advised to establish an accurate diagnosis. Based on the findings from the presented 2 cases, tumor cells positive for epithelial (CK) and endothelial markers (CD31, FLI-1), but negative to myogenic markers (EMA, SMA, vimentin and S-100) are vital to diagnose PHE. For unresectable or recurrent lesions, precision therapy targeting mutations detected by WES is a promising option that warrants further investigation. FUNDING This work was supported by the Key Nature Science Foundation of Tianjin (grant nos. 18YFZCSY00550 to Jilong Yang) ACKNOWLEDGEMENT Not applicable AUTHORS CONTRIBUTIONS JQW, ZCL, GZ, YY and JLY made substantial contributions to the conception and design of this work and the acquisition, analysis and interpretation of data. NN, CZ and JL made substantial contributions to the acquisition, analysis, and interpretation of data for the work. All authors have read and approved the final manuscript. AVAILABILITY OF DATA AND MATERIALS The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request ETHICS APPROVAL AND CONSENT TO PARTICIPATE The mTOR inhibitor everolimus was recommended for treatment and was approved by the review board at Tianjin Medical University Cancer Hospital. Written informed consent for everolimus as adjuvant therapy was obtained from the patient in accordance with the Declaration of Helsinki. CONSENT FOR PUBLICATION Not applicable COMPETING INTERESTS The author reports no conflicts of interest in this work. Supporting Information Filename Description cac212020-sup-0001-FigureS1.jpg257.5 KB Supporting information cac212020-sup-0001-SuppMat.pdf359.2 KB Supporting information cac212020-sup-0002-FigureS2.jpg305 KB Supporting information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Mirra JM, Kessler S, Bhuta S, Eckardt J. The fibroma-like variant of epithelioid sarcoma. A fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors. Cancer. 1992; 69(6): 1382– 1395. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 2Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol. 2011; 35(2): 190– 201. CrossrefPubMedWeb of Science®Google Scholar 3Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2): 95– 104. CrossrefCASPubMedWeb of Science®Google Scholar 4Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol. 2003; 27(1): 48– 57. CrossrefPubMedWeb of Science®Google Scholar 5Inyang A, Mertens F, Puls F, Sumathi V, Inwards V, Folpe A, et al. Primary Pseudomyogenic Hemangioendothelioma of Bone. Am J Surg Pathol. 2016; 40(5): 587– 598. CrossrefPubMedWeb of Science®Google Scholar 6Billings SD, Folpe AL, Weiss SW. Epithelioid Sarcoma-like hemangioendothelioma (pseudomyogenic hemangioendothelioma). Am J Surg Pathol. 2011; 35(7): 1088– 1089. Google Scholar 7Ozeki M, Nozawa A, Kanda K, Hori T, Nagano A, Shimada A, et al. Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma. J Pediatr Hematol Oncol. 2017; 39(6): e328– e331. CrossrefGoogle Scholar 8Gabor KM, Sapi Z, Tiszlavicz LG, Fige A, Bereczki C, Bartyik K. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Pediatr Blood Cancer. 2018; 65(2): e26781– e26785. Wiley Online LibraryGoogle Scholar 9Danforth OM, Jamulonis K, Vavra K, Oh C, Brickman A, Ebersole J, et al., Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature. J Pediatr Hematol Oncol. 2019; 41(5): 382– 387. CrossrefGoogle Scholar 10Joseph J, Wang WL, Patnana M, Ramesh N, Benjamin R, Patel S, et al. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clin Sarcoma Res. 2015; 5: 22– 28. CrossrefPubMedWeb of Science®Google Scholar 11Shapira M, Kakiashvili E, Rosenberg T, Hershko DD. The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006; 8(4): 46– 55. Google Scholar 12Geng Q, Liu J, Gong Z, Chen S, Chen S, Li X, et al. Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer. Mol Cancer. 2017; 16(1): 83– 95. CrossrefPubMedWeb of Science®Google Scholar 13Jin G, Lee SW, Zhang X, Cai Z, Gao Y, Chou PC, et al. Skp2-Mediated RagA Ubiquitination Elicits a Negative Feedback to Prevent Amino-Acid-Dependent mTORC1 Hyperactivation by Recruiting GATOR1. Mol Cell. 2015; 58(6): 989– 1000. CrossrefGoogle Scholar Volume40, Issue4April 2020Pages 197-201 FiguresReferencesRelatedInformation

Identification and Lineage Restriction Analyses of Preleukemia Cells in a Sporadic Biallelic CEBPA Mutated Acute Myeloid Leukemia Patient

Trisomy 21 in Patients with Acute Leukemia

Extramedullary T‐lymphoblastic Blast Crisis in Chronic Myeloid Leukemia: A Very Rare Case Associated with Comutation of ABL1 T315I and H396R

Prognostic Value of Post-Transplantation Wilms' Tumor Gene 1 Expression in Acute Myeloid Leukaemia Subgroup According to Different Pre-Transplant Disease Status

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Multiple Mutations Of Cebpa Contribute To Leukemogenesis: The Donor Origin Of Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation.

The Necessity of Studying Antibiotic Duration in Acute Leukemia Patients with Pseudomonas Aeruginosa Bloodstream Infection: A Response to Terada and Kanno

Identification and Clinical Implications of Recurrent PAX5::MLLT3 Fusion in Lymphoid Blastic Phase Chronic Myeloid Leukemia

Primary Pulmonary Non‐hodgkin's Lymphoma: A Retrospective Analysis of 29 Cases in a Chinese Population

Early T‐cell Precursor Acute Lymphoblastic Leukemia with Auer Rods in Mature Granulocytes

Clinicopathological Features of Pseudomyogenic Hemangioendothelioma and Precision Therapy Based on Whole Exome Sequencing

A Novel Missense Mutation, P.phe360cys, in FIX Gene Results in Haemophilia B in a Female Patient with Skewed X-inactivation

Clinical Characteristics of Two Patients with Α1‐antitrypsin Pittsburgh in a Chinese Family

Ott_a_280535 12163..12168

ABO Gene Mutation C.815_816insg in an African Individual Forms a Novel Ael Allele

Successful Chemotherapy for a Case of Therapy-Related ALL Withmllgene Rearrangement Following Treatment of Breast Cancer

Erratum To: Bone Marrow Mesenchymal Stromal Cells in Chronic Myelomonocytic Leukaemia: Overactivated WNT/β‐catenin Signalling by Parallel RNA Sequencing and Dysfunctional Phenotypes

Integrated Transcriptomic And Epigenetic Data Analysis Identifies Aberrant Expression Of Genes In Acute Myeloid Leukemia With Mll-Af9 Translocation (Vol 21, Pg 883, 2020)

The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

Generalized Pruritic Dark Papules in a Patient with T‐cell Prolymphocytic Leukemia – a Clinicopathological Challenge